Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

2.

Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies.

Wilinska ME, Budiman ES, Taub MB, Elleri D, Allen JM, Acerini CL, Dunger DB, Hovorka R.

J Diabetes Sci Technol. 2009 Sep 1;3(5):1109-20.

3.

Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.

Ly TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA.

Pediatr Diabetes. 2017 Aug;18(5):348-355. doi: 10.1111/pedi.12399. Epub 2016 May 18.

PMID:
27191182
4.

Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.

Haidar A, Legault L, Dallaire M, Alkhateeb A, Coriati A, Messier V, Cheng P, Millette M, Boulet B, Rabasa-Lhoret R.

CMAJ. 2013 Mar 5;185(4):297-305. doi: 10.1503/cmaj.121265. Epub 2013 Jan 28.

5.

Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.

Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA.

J Diabetes Sci Technol. 2014 Sep;8(5):1011-7. doi: 10.1177/1932296814542153. Epub 2014 Jul 16.

6.

The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.

Nimri R, Danne T, Kordonouri O, Atlas E, Bratina N, Biester T, Avbelj M, Miller S, Muller I, Phillip M, Battelino T.

Pediatr Diabetes. 2013 May;14(3):159-67. doi: 10.1111/pedi.12025. Epub 2013 Feb 28.

PMID:
23448393
7.

A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hyperglycemia in type 1 diabetes.

El Youssef J, Castle JR, Branigan DL, Massoud RG, Breen ME, Jacobs PG, Bequette BW, Ward WK.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1312-26.

8.

Factors influencing the effectiveness of glucagon for preventing hypoglycemia.

Castle JR, Engle JM, El Youssef J, Massoud RG, Ward WK.

J Diabetes Sci Technol. 2010 Nov 1;4(6):1305-10.

9.

Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon.

Jacobs PG, El Youssef J, Castle JR, Engle JM, Branigan DL, Johnson P, Massoud R, Kamath A, Ward WK.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:397-400. doi: 10.1109/IEMBS.2011.6090127.

PMID:
22254332
10.

Current topics in glycemic control by wearable artificial pancreas or bedside artificial pancreas with closed-loop system.

Hanazaki K, Munekage M, Kitagawa H, Yatabe T, Munekage E, Shiga M, Maeda H, Namikawa T.

J Artif Organs. 2016 Sep;19(3):209-18. doi: 10.1007/s10047-016-0904-y. Epub 2016 May 3. Review.

PMID:
27142278
11.

Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events.

Grosman B, Dassau E, Zisser HC, Jovanovic L, Doyle FJ 3rd.

J Diabetes Sci Technol. 2010 Jul 1;4(4):961-75.

12.

Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal bolus calculator - in silico evaluation under intra-day variability.

Herrero P, Bondia J, Adewuyi O, Pesl P, El-Sharkawy M, Reddy M, Toumazou C, Oliver N, Georgiou P.

Comput Methods Programs Biomed. 2017 Jul;146:125-131. doi: 10.1016/j.cmpb.2017.05.010. Epub 2017 Jun 1.

PMID:
28688482
13.

Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.

Bakhtiani PA, El Youssef J, Duell AK, Branigan DL, Jacobs PG, Lasarev MR, Castle JR, Ward WK.

J Diabetes Complications. 2015 Jan-Feb;29(1):93-8. doi: 10.1016/j.jdiacomp.2014.09.001. Epub 2014 Sep 16.

14.

Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review.

Golden SH, Sapir T.

J Manag Care Pharm. 2012 Aug;18(6 Suppl):S1-17. Review.

PMID:
22984955
15.

Feasibility study of automated overnight closed-loop glucose control under MD-logic artificial pancreas in patients with type 1 diabetes: the DREAM Project.

Nimri R, Atlas E, Ajzensztejn M, Miller S, Oron T, Phillip M.

Diabetes Technol Ther. 2012 Aug;14(8):728-35. doi: 10.1089/dia.2012.0004.

PMID:
22853723
16.

Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.

Rodbard D.

Diabetes Technol Ther. 2017 Jun;19(S3):S25-S37. doi: 10.1089/dia.2017.0035. Review.

17.

Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.

Ilkowitz JT, Katikaneni R, Cantwell M, Ramchandani N, Heptulla RA.

J Diabetes Sci Technol. 2016 Aug 22;10(5):1108-14. doi: 10.1177/1932296816647976. Print 2016 Sep.

18.

Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.

Russell SJ, El-Khatib FH, Nathan DM, Damiano ER.

J Diabetes Sci Technol. 2010 Nov 1;4(6):1288-304.

19.

Closed-loop artificial pancreas: current studies and promise for the future.

Weinzimer SA.

Curr Opin Endocrinol Diabetes Obes. 2012 Apr;19(2):88-92. doi: 10.1097/MED.0b013e3283514e6b. Review.

PMID:
22327368
20.

Amperometric glucose sensors: sources of error and potential benefit of redundancy.

Castle JR, Ward WK.

J Diabetes Sci Technol. 2010 Jan 1;4(1):221-5. Review.

Supplemental Content

Support Center